A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

LESSONS LEARNED: This study is a rare example of effective doses of both targeted agents being both administered and tolerated. This combination should not be used in melanoma. BACKGROUND. Sorafenib and bortezomib affect BCL family member expression. We previously demonstrated that bortezomib augmen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2015
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571786/
https://ncbi.nlm.nih.gov/pubmed/25986244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars